Evidence-Based Management of Diabetes in Older Adults

被引:0
作者
Arshag D. Mooradian
机构
[1] University of Florida College of Medicine,Department of Medicine
来源
Drugs & Aging | 2018年 / 35卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The number of older adults with diabetes is rapidly increasing worldwide. A variety of factors contribute to the age-related increase in the incidence of diabetes. The lack of empiric evidence in the field has limited the management guidelines to mostly expert opinion. Given uncertainty over the rate at which to lower blood glucose levels and the optimal method of doing so, the goals of diabetes control in older people must be individualized. If the patient requires insulin therapy, the newer insulins, with their improved pharmacodynamic consistency and reduced risk of hypoglycemia, should be preferred. Several oral agents are preferable for people with sufficient endogenous insulin because they do not cause hypoglycemia when used as monotherapy. Some of these oral agents have been found to have cardioprotective effects. Older people with diabetes also require management of the other risk factors for cardiovascular disease, with antihypertensive drugs, cholesterol-lowering agents and low-dose aspirin. However, the precise targets for blood pressure control and low-density lipoprotein (LDL) cholesterol levels continue to evolve as more data become available. Diabetes care in older adults should focus on enhancing the individual’s quality of life rather than trying to normalize blood glucose levels or reach predetermined blood pressure and LDL cholesterol targets.
引用
收藏
页码:1065 / 1078
页数:13
相关论文
共 431 条
  • [91] Kaiser FE(2018)Primary prevention with statins in the elderly J Am Coll Cardiol 71 85-94
  • [92] Evans SL(2004)Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685-696
  • [93] Nixon BP(2006)Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 1478-1485
  • [94] Lee I(2003)Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149-1158
  • [95] Yee D(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet Lond Engl 376 1670-1681
  • [96] Mooradian AD(2014)2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 S1-S45
  • [97] Mooradian AD(2002)MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet Lond Engl 360 7-22
  • [98] Korenman SG(2015)Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2387-2397
  • [99] Wachtel TJ(2017)Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 376 1713-1722
  • [100] Schwartz AV(2017)2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol 70 1785-1822